Navigation Links
Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
Date:2/7/2008

SEATTLE, Feb. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., chairman and chief executive officer of Dendreon, will present a company update at the 10th Annual BIO CEO & Investor Conference in New York City, on Wednesday, February 13, 2008 at 1:15 p.m. ET.

A live audio webcast of the presentation will be accessible through the Investor Relations section of the Dendreon website, http://www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
2. Dendreon Reports Third Quarter 2007 Financial Results
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. Dendreon Secures $130 Million Committed Equity Financing Facility
5. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
8. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
9. Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research
10. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... S.C. (PRWEB) , ... September 21, 2017 , ... ... turned bright neon green this month, the response was swift and efficient thanks ... ( RRWQG ). RRWQG is made up of more than 50 stakeholders, including ...
(Date:9/21/2017)... ... September 21, 2017 , ... Biorez, ... election of Paul Hermes, Entrepreneur in Residence at Medtronic, Inc., to serve as ... a proprietary, tissue-engineered scaffold for anterior cruciate ligament (ACL) reconstruction that is designed ...
(Date:9/20/2017)... ... September 20, 2017 , ... Cybrexa Therapeutics ... Paralkar to the role of chief scientific officer. In this role, Dr. Paralkar ... Cybrexa’s president and CEO, Per Hellsund. , “I was impressed with Cybrexa’s revolutionary ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... leading global provider of engineering, architecture, project controls, construction management, commissioning and ... today announced the unveiling of the iCON™ brand which represents the collective ...
Breaking Biology Technology:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
Breaking Biology News(10 mins):